Teva’s push to keep generic Copaxone off the market its over. Bloomberg reports the company lost its suit to keep generics at bay, just 10 days before the expiration of the branded MS drug’s patent.
Teva wanted more testing of generic versions of the drug, but a federal judge said forget it.
The company has prepped investors for the possibility that its major drug could get competition this year, and even went so far as to provide two 2014 forecasts: one in which Copaxone had the market to itself, and other in which it did not.
Despite generics concern, the company has been able to convert Copaxone users to a newer, patent-protected formulation.
